English translation:

The protocol being carried out by UBA scientists shows promising results for the treatment and prevention of the disease.

Preliminary results were released, from May 27 to June 26, of two protocols using ivermectin carried out by scientists from the University of Buenos Aires (UBA) at the Doctor A. Eurnekian Hospital in Ezeiza.

The first protocol consists of medication for cases of mild patients (ivermectin and aspirin), moderate (ivermectin, aspirin and dexamethasone) and severe (ivermectin, dexamethasone and enoxaparin). In the second protocol, intended for healthy hospital personnel, a nasal spray and oral drops are administered to protect the nose and mouth.

Hector Carvallo, former assistant professor of Internal Medicine at the UBA, is in charge of both protocols and he carries it out along with other professionals from the UBA, the Hospital Muñiz and Hospital de Ezeiza.

Between May 27 and June 26, 161 patients were diagnosed in the protocol. Mild and / or asymptomatic (138 cases, 85.7% of the total) were treated on an outpatient basis. In some cases, due to housing deficiencies, they were relocated to ad hoc refugee centers. On the 15th day of their respective diagnoses, none required to be admitted to the Hospital. In all cases, these outpatients received Ivermectin (24 mg orally as a single dose, repeated one week later) and aspirin (250 mg / day, every day).

The remaining cases were moderate (10) and severe (13), with bilateral pneumonia, in some cases with comorbidities (COPD, cancer, diabetes, epilepsy, among others). Each patient received the therapeutic scheme and the dose appropriate to their categorization.

As for the evolution of these cases, in 15 it was good and high; in 4 it was good and they are still hospitalized and 3 cases are stable. A single death occurred in an 80-year-old person.

As Héctor Carvallo explained to Super Campo, this experience shows that with Ivermectin treatment “the passage from mild to moderate or severe forms is reduced. On the other hand, in the forms that debut as moderate or severe, it reduces the passage to critical forms and death. In addition, recovery times are partially reduced because of the 23 moderate to severe patients who required hospitalization, many were discharged when some moderate patients usually stay 3-4 weeks. "

Carvallo highlighted that at this stage of the protocol, “65% of patients aged 43 to 65 include a vulnerable population. This is important because at the beginning it was thought that the vulnerable population was the population with more than 80 years, then it dropped to 70 and today it is being seen that the average is 50 years. If the average of those who were treated was 53.6 years, it means that the focus was on the most affected age group ”.

The scientist highlighted the importance of early treatment for patients: “A person who came with suspicious symptoms and good general condition, at the time of the swab, was given the protocol medications to start taking them (ivermectin and aspirin). Two days later, if the swab test was positive for coronavirus, she was instructed to continue treatment. If he tested negative, he was asked to suspend it. "

Furthermore, the nasal spray administration protocol as a complement to the protection elements was carried out on 105 people who are part of the medical and non-medical personnel of the hospital. In this case, no case of coronavirus occurred.

For Carvallo, this shows that "preventive treatment is effective as a complement to personal protective equipment, that is, it increases their efficiency".

permalink

Adding some commentary (this is how I "consume" articles; it helps me understand them, if I go through them making my observations):

The first protocol consists of medication for cases of mild patients (ivermectin and aspirin), moderate (ivermectin, aspirin and dexamethasone) and severe (ivermectin, dexamethasone and enoxaparin).

A clinical trial of these 3 drugs is underway, out of Argentina, not a coincidence: Dr. Carvallo is identified as the source of the information on ClinicalTrials. Primary completion date: June 30! Estimated study completion date (publication date?) is July 30.

Interesting that they were using dexamethasone before the big UK study came out last week. Smart people!

Between May 27 and June 26, 161 patients were diagnosed in the protocol. Mild and / or asymptomatic (138 cases, 85.7% of the total) were treated on an outpatient basis.

Just one month of data collection, to get a decent N! Excellent! Why do other trials take 3 or 6 months?

No apparent provision for those at home with the patients? In some locales, they send home ivermectin (plus other drugs) for family members / roommates.

On the 15th day of their respective diagnoses, none required to be admitted to the Hospital.

Which is different from "tested negative for the virus" or "were free of symptoms". I guess it means the disease did not advance, a very good thing.

In all cases, these outpatients received Ivermectin (24 mg orally as a single dose, repeated one week later) and aspirin (250 mg / day, every day).

As DZinni points out, this is a middling-hefty dose, 331 mcg/kg compared to the typical 200 mcg/kg.

A re-dose a week later appears to be an emerging consensus. Maybe. IIRC.

The remaining cases were moderate (10) and severe (13), with bilateral pneumonia, in some cases with comorbidities (COPD, cancer, diabetes, epilepsy, among others). Each patient received the therapeutic scheme and the dose appropriate to their categorization.

The protocol details are laid out here. Sicker patients got more ivermectin.

I wish they had more patients who were really ill. The chances of statistically significant results are not good, with such low numbers.

As for the evolution of these cases, in 15 it was good and high; in 4 it was good and they are still hospitalized and 3 cases are stable. A single death occurred in an 80-year-old person.

Good and high? Anyone know what that means? Does anyone read Spanish so they can give a better translation?

I'll read it as "15 of 23 moderately and severely ill patients were released from the hospital; another 4 patients are doing well. Only one patient died, and he was 80!"

That's a great result -- but it leaves (23 - 15 - 4 - 1 =) 3 patients unreported. Are they not doing well?

As Héctor Carvallo explained to Super Campo, this experience shows that with Ivermectin treatment “the passage from mild to moderate or severe forms is reduced.

Suggestive of ivermectin as prophylaxis? Not really, I guess.

Stopping the advancement of the disease is great!

On the other hand, in the forms that debut as moderate or severe, it reduces the passage to critical forms and death. In addition, recovery times are partially reduced because of the 23 moderate to severe patients who required hospitalization, many were discharged when some moderate patients usually stay 3-4 weeks."

How long until they were discharged? We don't know how much the length of stay was shortened, if you don't tell us, Doctor! :(

Carvallo highlighted that at this stage of the protocol, “65% of patients aged 43 to 65 include a vulnerable population. This is important because at the beginning it was thought that the vulnerable population was the population with more than 80 years, then it dropped to 70 and today it is being seen that the average is 50 years. If the average of those who were treated was 53.6 years, it means that the focus was on the most affected age group”.

The average what is 50 years? Patient who tested positive? Sounds like they had a lot of younger patients for whom advancement to more serious illness is unlikely.

Or maybe not: the average age of the ICON study was 59.something, IIRC. Confused.

The scientist highlighted the importance of early treatment for patients: “A person who came with suspicious symptoms and good general condition, at the time of the swab, was given the protocol medications to start taking them (ivermectin and aspirin). Two days later, if the swab test was positive for coronavirus, she was instructed to continue treatment. If he tested negative, he was asked to suspend it."

I guess they had to wait a couple days to get the test results. I like the preemptive use of ivermectin.

Furthermore, the nasal spray administration protocol as a complement to the protection elements was carried out on 105 people who are part of the medical and non-medical personnel of the hospital. In this case, no case of coronavirus occurred.

This might be the most starting result. 0 out of 105 staffers caught the virus?

For Carvallo, this shows that "preventive treatment is effective as a complement to personal protective equipment, that is, it increases their efficiency".

Well, not really, unless there were other staffers who did not do the nasal spray and did catch covid19.

permalink

Finally, a study with results. Thanks everyone! I hope this gets picked up by MSM

permalink